NO20056236L - Behandling med anti-VEGF-antistoffer - Google Patents

Behandling med anti-VEGF-antistoffer

Info

Publication number
NO20056236L
NO20056236L NO20056236A NO20056236A NO20056236L NO 20056236 L NO20056236 L NO 20056236L NO 20056236 A NO20056236 A NO 20056236A NO 20056236 A NO20056236 A NO 20056236A NO 20056236 L NO20056236 L NO 20056236L
Authority
NO
Norway
Prior art keywords
treatment
vegf antibodies
vegf
relates
diagnosed
Prior art date
Application number
NO20056236A
Other languages
English (en)
Norwegian (no)
Inventor
Gwendolyn Fyfe
Eric Holmgren
Robert D Mass
William Novotny
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551495&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20056236(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20056236L publication Critical patent/NO20056236L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
NO20056236A 2003-05-30 2005-12-29 Behandling med anti-VEGF-antistoffer NO20056236L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47448003P 2003-05-30 2003-05-30
PCT/US2004/017078 WO2005000900A1 (en) 2003-05-30 2004-05-28 Treatment with anti-vegf antibodies

Publications (1)

Publication Number Publication Date
NO20056236L true NO20056236L (no) 2006-02-28

Family

ID=33551495

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056236A NO20056236L (no) 2003-05-30 2005-12-29 Behandling med anti-VEGF-antistoffer

Country Status (23)

Country Link
US (41) US20050186208A1 (zh)
EP (4) EP1629010A1 (zh)
JP (8) JP2007525466A (zh)
KR (11) KR20190085166A (zh)
CN (2) CN101274098A (zh)
AU (2) AU2004251168A1 (zh)
BR (1) BRPI0411200A (zh)
CA (1) CA2526085A1 (zh)
CO (1) CO5640150A2 (zh)
CR (1) CR8108A (zh)
EC (1) ECSP056187A (zh)
IL (4) IL171833A (zh)
MA (1) MA27854A1 (zh)
ME (1) ME00425B (zh)
MX (1) MXPA05012723A (zh)
NO (1) NO20056236L (zh)
NZ (1) NZ621449A (zh)
RS (5) RS20150135A1 (zh)
RU (4) RU2005136988A (zh)
TN (1) TNSN05300A1 (zh)
UA (1) UA101945C2 (zh)
WO (1) WO2005000900A1 (zh)
ZA (1) ZA200509059B (zh)

Families Citing this family (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
DE60237282D1 (de) * 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
PT1517921E (pt) * 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
KR20120104412A (ko) 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
EP2301531B1 (en) 2005-02-18 2018-06-06 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2616008A1 (en) * 2005-07-21 2007-01-25 Stefan Meuer Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
US8023114B2 (en) 2005-08-01 2011-09-20 Canon Kabushiki Kaisha Target substance detecting device, target substance detecting method using the same, and detecting apparatus and kit therefor
JP4878238B2 (ja) * 2005-08-01 2012-02-15 キヤノン株式会社 標的物質検出用の素子及びそれを用いた標的物質の検出方法、並びにそのための検出装置及びキット
CN101237880B (zh) * 2005-08-12 2011-09-21 瑞泽恩制药公司 通过vegf拮抗剂的皮下给药治疗疾病
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
KR101420445B1 (ko) 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
TW200730539A (en) * 2005-12-01 2007-08-16 Domantis Ltd Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CN101448856A (zh) * 2006-03-29 2009-06-03 健泰科生物技术公司 肿瘤的诊断和治疗
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
CA2648947A1 (en) * 2006-04-10 2007-11-15 Fusion Antibodies Limited Therapy targeting cathepsin s
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
US8093259B2 (en) * 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
CA2654304A1 (en) * 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
JP2009539999A (ja) * 2006-06-15 2009-11-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 第２の薬剤との組み合わせにおいてリンホトキシンベータ受容体結合分子を使用する複合療法
EP2441472B1 (en) * 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
LT2117520T (lt) 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną
SG10201503407WA (en) * 2006-12-19 2015-06-29 Genentech Inc Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
EP2125013A4 (en) * 2007-01-26 2010-04-07 Bioinvent Int Ab DLL4 SIGNALING INHIBITOR AND ITS USES
EP2125016A2 (en) * 2007-02-01 2009-12-02 Genetech, Inc. Combination therapy with angiogenesis inhibitors
KR20100040840A (ko) 2007-06-06 2010-04-21 도만티스 리미티드 폴리펩티드，항체 가변 도메인 및 길항제
CL2008002782A1 (es) * 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US11331294B2 (en) 2007-09-26 2022-05-17 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
ES2653855T3 (es) 2007-09-26 2018-02-09 Indiana University Research And Technology Corporation Derivado de la benzoquinona e3330 en combinación con agentes quimioterapéuticos para el tratamiento del cáncer y la angiogénesis
CN101918579A (zh) * 2007-10-22 2010-12-15 先灵公司 完全人抗-vegf抗体和使用方法
CA2703099A1 (en) * 2007-11-09 2009-05-14 Genentech, Inc. Activin receptor-like kinase-i compositions and methods of use
AR069501A1 (es) * 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP2011508738A (ja) * 2007-12-26 2011-03-17 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８発現腫瘍細胞のターゲティングを向上させる方法及び剤
US8580755B2 (en) * 2008-02-19 2013-11-12 University Of Rochester Methods and compositions for treating inflammatory conditions
US20110159080A1 (en) * 2008-06-03 2011-06-30 Colin Lowery Composition comprising liposome-entrapped doxorubicin and methods of administration
RU2514658C2 (ru) 2008-06-25 2014-04-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Оптимизация растворимости иммуносвязывающих средств
CN110372792A (zh) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
ES2644723T3 (es) * 2008-07-23 2017-11-30 F. Hoffmann-La Roche Ag Identificación de sujetos susceptibles de tratamiento antiangiogénico
WO2010010155A1 (en) * 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Monitoring anti-angiogenesis therapy
TW201012935A (en) * 2008-08-29 2010-04-01 Genentech Inc Diagnostics and treatments for VEGF-independent tumors
KR101705911B1 (ko) 2008-09-03 2017-02-10 제넨테크, 인크. 다중특이적 항체
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR20190025057A (ko) 2008-10-14 2019-03-08 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
EP2752189B1 (en) * 2008-11-22 2016-10-26 F. Hoffmann-La Roche AG Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
US20100143290A1 (en) * 2008-12-04 2010-06-10 Lallatin Nathaniel C Monoclonal antibodies to human thymidine kinase to treat cancer
KR101596539B1 (ko) 2008-12-23 2016-02-22 제넨테크, 인크. 암 환자에서의 진단 목적용 방법 및 조성물
EP2386062B1 (en) * 2009-01-09 2016-01-06 Oxford Biomedica (UK) Ltd Factors
US9186336B2 (en) 2009-02-06 2015-11-17 The General Hospital Corporation Methods of treating vascular lesions
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
MA33323B1 (fr) * 2009-04-20 2012-06-01 Genentech Inc Thérapie adjuvante de cancer
CN108912228B (zh) 2009-05-08 2022-03-15 瓦西尼斯公司 抗-cd100抗体和其使用方法
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
MX346002B (es) * 2009-06-17 2017-03-01 Abbvie Biotherapeutics Inc Anticuerpos anti-vegf y sus usos.
SG10201510152RA (en) 2009-07-13 2016-01-28 Genentech Inc Diagnostic methods and compositions for treatment of cancer
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
NZ597531A (en) 2009-07-31 2014-05-30 Genentech Inc Inhibition of tumor metastasis using bv8- or g-csf-antagonists
WO2011022264A1 (en) * 2009-08-15 2011-02-24 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
US20180057602A1 (en) * 2009-08-17 2018-03-01 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
KR101553740B1 (ko) * 2009-08-17 2015-09-17 트라콘 파마수티칼즈, 인코포레이티드 항엔도글린 항체 및 항ｖｅｇｆ 제제를 사용한 암 치료를 위한 병용 요법
WO2011028642A1 (en) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
AU2010292060A1 (en) 2009-09-11 2012-04-12 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
CN102612566B (zh) 2009-09-17 2016-02-17 霍夫曼-拉罗奇有限公司 用于癌症患者中诊断学用途的方法和组合物
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
EP2493458A2 (en) * 2009-10-30 2012-09-05 The Ohio State University Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders
EP2499159B1 (en) 2009-11-13 2017-01-04 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗－ｖｅｇｆ－ｃ抗體及其使用方法
KR101989628B1 (ko) 2009-12-21 2019-06-14 제넨테크, 인크. 항체 제제
SI2516465T1 (sl) 2009-12-23 2016-08-31 F. Hoffmann-La Roche Ag Protelesa proti bv8 in uporaba le-teh
AU2011221229B2 (en) * 2010-02-23 2015-06-18 F. Hoffmann-La Roche Ag Anti-angiogenesis therapy for the treatment of ovarian cancer
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2011123395A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
NZ604031A (en) 2010-06-04 2015-05-29 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
JP2013538338A (ja) 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法
SG187018A1 (en) 2010-07-19 2013-02-28 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012012750A1 (en) 2010-07-23 2012-01-26 Trustees Of Boston University ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
KR101910779B1 (ko) 2010-11-15 2018-10-22 파이브 프라임 테라퓨틱스, 인크. Ｆｇｆｒ１ 세포밖 도메인 조합치료
AR084053A1 (es) 2010-11-30 2013-04-17 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
ES2549638T3 (es) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Proteínas de unión a antígeno
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
SG194048A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
CA2833747C (en) 2011-04-20 2022-10-18 Asya Grinberg Endoglin polypeptides and uses thereof
JP2014513128A (ja) 2011-05-03 2014-05-29 ジェネンテック， インコーポレイテッド 血管破壊剤とその使用
MX2013014065A (es) * 2011-06-02 2014-06-23 Almac Diagnostics Ltd Prueba diagnóstica molecular para el cancer.
WO2012167122A1 (en) 2011-06-03 2012-12-06 Indiana University Research And Technology Corporation Compounds, compositions and methods for treating oxidative dna damage disorders
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
CN103890008A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
JP6271432B2 (ja) 2011-09-30 2018-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥｒｂＢ３抗体およびその使用
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US10350188B2 (en) * 2011-11-04 2019-07-16 Myron R. Szewczuk Use of Neu1 sialidase inhibitors in the treatment of cancer
BR112014012005A2 (pt) 2011-11-21 2017-12-19 Genentech Inc composições, métodos, formulação farmacêutica e artigo
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
FR2984750B1 (fr) * 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
PT2825558T (pt) 2012-03-13 2019-07-11 Hoffmann La Roche Terapêutica combinada para o tratamento do cancro do ovário
EP2830648A4 (en) * 2012-03-29 2015-12-02 Altor Bioscience Corp METHODS OF TREATING NEOPLASIA
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
BR112014028600B1 (pt) * 2012-05-18 2022-11-22 Genentech, Inc Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
EP3556776A1 (en) 2012-05-31 2019-10-23 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014001324A1 (en) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
US9415098B2 (en) 2012-07-05 2016-08-16 Vaximm Ag DNA vaccine for use in pancreatic cancer patients
HUE056217T2 (hu) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
EP2882454B1 (en) 2012-08-07 2018-10-10 F.Hoffmann-La Roche Ag Combination therapy for the treatment of glioblastoma
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
EP2925885B1 (en) 2012-12-03 2020-02-05 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
CA2930987A1 (en) 2013-01-11 2014-07-17 Massachusetts Eye And Ear Infirmary Cyp450 lipid metabolites reduce inflammation and angiogenesis
US9500464B2 (en) * 2013-03-12 2016-11-22 Adidas Ag Methods of determining performance information for individuals and sports objects
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3607821B1 (en) * 2013-03-15 2022-08-03 EyePoint Pharmaceuticals, Inc. Compositions, formulations and methods for treating ocular diseases
PT3611180T (pt) 2013-03-15 2022-03-15 Biomolecular Holdings Llc Imunoglobulina híbrida que contém uma ligação não peptídica
CA2909689A1 (en) 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
MX2015017485A (es) 2013-06-25 2016-03-31 Vaccinex Inc Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis.
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
MX2016003593A (es) 2013-10-11 2016-06-02 Hoffmann La Roche Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
KR20220013459A (ko) 2013-10-25 2022-02-04 악셀레론 파마 인코포레이티드 섬유화 질환을 치료하기 위한 엔도글린 펩티드
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
CN106103484B (zh) 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
SI3701971T1 (sl) 2014-03-14 2023-01-31 Biomolecular Holdings LLC, Spojine, uporabne v pripravi hibridnega imunoglobulina, ki vsebuje nepeptidilno vezavo
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
BR112016024462B1 (pt) 2014-05-06 2022-12-27 Genentech, Inc Métodos para a preparação de um anticorpo
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
DK3180018T3 (da) 2014-08-12 2019-10-28 Massachusetts Inst Technology Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
BR112017004393A2 (pt) 2014-09-15 2018-02-27 Genentech Inc formulações de anticorpo
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
CR20170240A (es) 2014-11-10 2018-04-03 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
WO2016089960A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
RU2710735C2 (ru) 2014-12-23 2020-01-10 Дженентек, Инк. Композиции и способы лечения и диагностики резистентного к химиотерапии рака
NO3040075T3 (zh) * 2014-12-30 2018-02-10
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
CN107787332B (zh) 2015-04-24 2022-09-09 豪夫迈·罗氏有限公司 多特异性抗原结合蛋白
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
IL300548A (en) 2015-05-20 2023-04-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
CA2988420A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
EA036789B1 (ru) 2015-06-22 2020-12-22 Янссен Байотек, Инк. Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
RU2760185C2 (ru) 2015-08-20 2021-11-22 Ипсен Биофарм Лтд. Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака
WO2017034957A1 (en) 2015-08-21 2017-03-02 Merrimack Pharmaceuticals, Inc. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
HUE054093T2 (hu) 2015-10-30 2021-08-30 Hoffmann La Roche Anti-HtrA1 antitestek és azok alkalmazási eljárásai
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
TWI800341B (zh) 2015-11-03 2023-04-21 美商健生生物科技公司 抗cd38抗體之皮下調配物及其用途
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CA3007671A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
TW202342540A (zh) 2016-03-14 2023-11-01 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
WO2017165681A1 (en) 2016-03-24 2017-09-28 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
ES2850428T3 (es) 2016-04-15 2021-08-30 Hoffmann La Roche Procedimientos de monitorización y tratamiento del cáncer
JP2019515670A (ja) 2016-04-15 2019-06-13 ジェネンテック， インコーポレイテッド がんをモニタリングし治療するための方法
JP2019524706A (ja) 2016-07-08 2019-09-05 ジェネンテック， インコーポレイテッド Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
CN109890982B (zh) 2016-07-08 2023-07-07 基因泰克公司 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
SG10201912338RA (en) 2016-11-02 2020-02-27 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
US10603358B2 (en) 2017-01-10 2020-03-31 Nodus Therapeutics Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
TW201837467A (zh) 2017-03-01 2018-10-16 美商建南德克公司 用於癌症之診斷及治療方法
JP7433910B2 (ja) 2017-06-22 2024-02-20 ノバルティス アーゲー Ｃｄ７３に対する抗体分子及びその使用
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
CN111479588A (zh) 2017-12-29 2020-07-31 豪夫迈·罗氏有限公司 用于改善抗vegf抗体的vegf受体阻断选择性的方法
EP3782618A4 (en) 2018-04-16 2022-01-26 OnQuality Pharmaceuticals China Ltd. METHOD OF PREVENTING OR TREATING SIDE EFFECTS OF CANCER THERAPY
EP3802609A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Psma binding agents and uses thereof
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020006511A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Trispecific antagonists
MX2021004348A (es) 2018-10-18 2021-05-28 Genentech Inc Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
CN113747944A (zh) 2019-04-19 2021-12-03 詹森生物科技公司 用抗psma/cd3抗体治疗***癌的方法
AU2020270376A1 (en) 2019-05-03 2021-10-07 Genentech, Inc. Methods of treating cancer with an anti-PD-L1 antibody
CN112010971A (zh) * 2019-05-30 2020-12-01 义慧科技(深圳)有限公司 抗vegf抗体在制备预防和/或治疗脂肪肝的药物中的应用
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021183849A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
KR20230033647A (ko) 2020-06-30 2023-03-08 멘두스 비.브이. 난소암 백신에서 백혈병 유래 세포의 용도
TW202224682A (zh) 2020-11-13 2022-07-01 美商建南德克公司 用於治療實性瘤之方法與包含ｋｒａｓｇ１２ｃ抑制劑及ｖｅｇｆ抑制劑之組成物
CA3203705A1 (en) 2021-01-22 2022-07-28 Erik Hans MANTING Methods of tumor vaccination
BR112023015097A2 (pt) 2021-01-28 2023-10-03 Janssen Biotech Inc Proteínas de ligação a psma e usos das mesmas
US20220305100A1 (en) 2021-03-12 2022-09-29 Dcprime B.V. Methods of vaccination and use of cd47 blockade
KR20220141572A (ko) 2021-04-13 2022-10-20 김문재 확장형 실내 캠핑실이 삽입 및 인출되는 차량
JP2024516230A (ja) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド がんのための治療及び診断方法並びに組成物
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
CN113244388A (zh) * 2021-07-01 2021-08-13 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
BR112023026966A2 (pt) 2021-07-02 2024-03-12 Hoffmann La Roche Métodos para tratar um indivíduo com melanoma, para alcançar uma resposta clínica, para tratar um indivíduo com linfoma não hodgkin, para tratar uma população de indivíduos com linfoma não hodgkin e para tratar um indivíduo com câncer colorretal metastático
AU2022317820A1 (en) 2021-07-28 2023-12-14 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5036003A (en) 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
CA2083401C (en) 1991-02-22 2003-03-25 Bruce I. Terman Identification of a novel human receptor tyrosine kinase gene
US20010021382A1 (en) 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
OA10149A (en) 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
US20020032313A1 (en) 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
CA2145985C (en) 1992-10-28 2003-09-16 Napoleone Ferrara Vascular endothelial cell growth factor antagonists
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20060193862A1 (en) 1995-03-30 2006-08-31 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
JPH10114680A (ja) 1996-10-08 1998-05-06 Toagosei Co Ltd 制癌剤
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20150023951A1 (en) 1997-04-07 2015-01-22 Genentech, Inc. Anti-vegf antibodies
EP0973804B1 (en) 1997-04-07 2006-12-27 Genentech, Inc. Anti-vegf antibodies
EP3260468A1 (en) 1997-04-07 2017-12-27 Genentech, Inc. Anti-vegf antibodies
PT1860187E (pt) 1997-05-15 2011-10-04 Genentech Inc Receptor apo-2
WO1999037684A1 (en) 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
DE60036915T2 (de) 1999-01-13 2008-08-07 Alchemia Oncology Pty Ltd., Hawthorn Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
RU2177349C1 (ru) 2001-02-20 2001-12-27 Центральный научно-исследовательский рентгено-радиологический институт МЗ РФ Способ лечения инфильтративно-отечного рака молочной железы
AU2003213682C1 (en) 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
CN1187373C (zh) 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
US20070036755A1 (en) 2004-05-28 2007-02-15 Genentech, Inc. Treatment with anti-vegf antibodies
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

Also Published As

Publication number Publication date
US20130195847A1 (en) 2013-08-01
RU2017109912A3 (zh) 2020-05-28
JP2011144188A (ja) 2011-07-28
KR20180014881A (ko) 2018-02-09
RS20170595A1 (sr) 2017-09-29
JP2007525466A (ja) 2007-09-06
RS20181002A1 (sr) 2018-12-31
ECSP056187A (es) 2006-04-19
US20230218755A1 (en) 2023-07-13
MA27854A1 (fr) 2006-04-03
US20080279860A1 (en) 2008-11-13
US20070071748A1 (en) 2007-03-29
US20070036790A1 (en) 2007-02-15
IL235814A0 (en) 2014-12-31
US20090010881A1 (en) 2009-01-08
KR20190085166A (ko) 2019-07-17
WO2005000900A1 (en) 2005-01-06
AU2008243227A1 (en) 2008-12-04
JP2007326860A (ja) 2007-12-20
US20200171148A1 (en) 2020-06-04
NZ621449A (en) 2015-07-31
EP1629010A1 (en) 2006-03-01
CA2526085A1 (en) 2005-01-06
KR20110118738A (ko) 2011-10-31
KR20200034817A (ko) 2020-03-31
ZA200509059B (en) 2007-01-31
US20190307881A1 (en) 2019-10-10
CN101274098A (zh) 2008-10-01
RU2017109912A (ru) 2019-01-23
US20160310592A1 (en) 2016-10-27
AU2004251168A1 (en) 2005-01-06
RU2014109776A (ru) 2015-09-20
US20070031413A1 (en) 2007-02-08
US20070154483A1 (en) 2007-07-05
US20180221473A1 (en) 2018-08-09
US20080292630A1 (en) 2008-11-27
KR20150008458A (ko) 2015-01-22
US20080241148A1 (en) 2008-10-02
IL246594A0 (en) 2016-08-31
JP2019055965A (ja) 2019-04-11
US20080166351A1 (en) 2008-07-10
KR20160114727A (ko) 2016-10-05
IL232718A0 (en) 2014-07-31
CO5640150A2 (es) 2006-05-31
US7622115B2 (en) 2009-11-24
US20080267968A1 (en) 2008-10-30
US20080248049A1 (en) 2008-10-09
US20070036753A1 (en) 2007-02-15
CR8108A (es) 2007-06-20
KR20120104408A (ko) 2012-09-20
US20160304594A1 (en) 2016-10-20
RU2005136988A (ru) 2006-06-10
US20210015918A1 (en) 2021-01-21
KR20170073698A (ko) 2017-06-28
US20080248036A1 (en) 2008-10-09
JP2013224301A (ja) 2013-10-31
RU2009149451A (ru) 2011-07-10
US20070148177A1 (en) 2007-06-28
US20070160608A1 (en) 2007-07-12
RS20160203A1 (sr) 2016-10-31
KR20180132969A (ko) 2018-12-12
US20090053216A1 (en) 2009-02-26
RU2519669C2 (ru) 2014-06-20
CN1829741A (zh) 2006-09-06
US20070148178A1 (en) 2007-06-28
UA101945C2 (uk) 2013-05-27
US20070025999A1 (en) 2007-02-01
US20070071749A1 (en) 2007-03-29
US20080292631A1 (en) 2008-11-27
US20090246173A1 (en) 2009-10-01
BRPI0411200A (pt) 2006-07-18
US20050186208A1 (en) 2005-08-25
EP2311875A1 (en) 2011-04-20
EP2248829A1 (en) 2010-11-10
JP2020121984A (ja) 2020-08-13
MXPA05012723A (es) 2006-02-08
US20080160029A1 (en) 2008-07-03
US20070036754A1 (en) 2007-02-15
US20090010883A1 (en) 2009-01-08
JP2018012705A (ja) 2018-01-25
RS20050885A (sr) 2008-04-04
KR20160014775A (ko) 2016-02-11
US20100226880A1 (en) 2010-09-09
US20140178369A1 (en) 2014-06-26
IL171833A (en) 2014-12-31
TNSN05300A1 (en) 2007-07-10
US20070071718A1 (en) 2007-03-29
KR20060006975A (ko) 2006-01-20
US20090191215A1 (en) 2009-07-30
US20070258984A1 (en) 2007-11-08
ME00425B (me) 2011-10-10
US20150359881A1 (en) 2015-12-17
US20130028862A1 (en) 2013-01-31
US20110123494A1 (en) 2011-05-26
US9795672B2 (en) 2017-10-24
RS20150135A1 (en) 2015-08-31
EP2251355A1 (en) 2010-11-17
JP2016074681A (ja) 2016-05-12

Similar Documents

Publication Publication Date Title
NO20056236L (no) Behandling med anti-VEGF-antistoffer
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
NO20070782L (no) Tetrapeptidanaloger.
NO20050775L (no) Fremgangsmater for identifisering av tumorer som responderer pa behandling med anti-ErbB2-antistoffer
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
NO20071791L (no) Preparater og fremgangsmater for diagnostiseringen og behandlingen av tumor
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
DK1869085T3 (da) Hidtil ukendt anti-PLGF-antistof
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
WO2011106300A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
UA109633C2 (uk) Антитіло людини проти тканинного фактора
UA85559C2 (en) Aminobenzophenone compounds
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
NO20070854L (no) Humane monoklonale antistoffer mot humant IL-4.
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele